Jump to content

AKS-452

From Wikipedia, the free encyclopedia

AKS-452
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number

AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.[2][3]

References

[edit]
  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
  3. ^ "A study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Сov-2 infection in Indian healthy subjects". ctri.nic.in. 11 October 2021. CTRI/2021/10/037269. Retrieved 11 October 2021.